Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$573M |
| 2 |
Microsoft
MSFT
|
+$529M |
| 3 |
McDonald's
MCD
|
+$469M |
| 4 |
Walt Disney
DIS
|
+$303M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$291M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$482M |
| 2 |
Comcast
CMCSA
|
+$481M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$381M |
| 4 |
Sherwin-Williams
SHW
|
+$374M |
| 5 |
CELG
Celgene Corp
CELG
|
+$341M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.22% |
| 2 | Technology | 7.41% |
| 3 | Consumer Discretionary | 6.04% |
| 4 | Financials | 5.89% |
| 5 | Industrials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6801
CALL
Rocket Pharmaceuticals
RCKT
$280M
| $69K | ﹤0.01% |
8,650
+4,050
| +88% | +$27.2K |
2016 Q4
1 quarter
|
|
|
KONA
6802
CALL
DELISTED
Kona Grill, Inc.
KONA
| $69K | ﹤0.01% |
+11,000
| New | +$88.7K |
2017 Q1
0 quarters
|
|
|
STB
6803
DELISTED
Student Transportation Inc
STB
| $69K | ﹤0.01% |
11,736
-1,464
| -11% | -$8.19K |
2016 Q4
1 quarter
|
|
|
PDS
6804
PUT
Precision Drilling
PDS
$1.07B
| $68K | ﹤0.01% |
720
+130
| +22% | +$13.6K |
2016 Q4
1 quarter
|
|
6805
PUT
QuickLogic
QUIK
$212M
| $67K | ﹤0.01% |
2,700
-264
| -9% | -$6.04K |
2016 Q4
1 quarter
|
|
|
SEEL
6806
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| – | – |
0
| – | – |
2017 Q1
0 quarters
|
|
|
PETX
6807
CALL
DELISTED
Aratana Therapeutics, Inc.
PETX
| $67K | ﹤0.01% |
+12,600
| New | +$85.1K |
2017 Q1
0 quarters
|
|
6808
CALL
MannKind Corp
MNKD
$1.21B
| $66K | ﹤0.01% |
44,300
-18,180
| -29% | -$47.7K |
2013 Q2
15 quarters
|
|
|
TRQ
6809
CALL
DELISTED
Turquoise Hill Resources Ltd
TRQ
| $66K | ﹤0.01% |
+2,160
| New | +$72.8K |
2017 Q1
0 quarters
|
|
|
PDLI
6810
CALL
DELISTED
PDL BioPharma, Inc.
PDLI
| $66K | ﹤0.01% |
29,100
-13,100
| -31% | -$29K |
2013 Q2
15 quarters
|
|
|
PDLI
6811
PUT
DELISTED
PDL BioPharma, Inc.
PDLI
| $66K | ﹤0.01% |
29,100
+14,300
| +97% | +$31.6K |
2016 Q4
1 quarter
|
|
|
CARM
6812
DELISTED
Carisma Therapeutics
CARM
| $65K | ﹤0.01% |
+1,480
| New | +$61.7K |
2017 Q1
0 quarters
|
|
|
VVUS
6813
CALL
DELISTED
Vivus Inc
VVUS
| $65K | ﹤0.01% |
5,760
-2,310
| -29% | -$26.2K |
2013 Q2
15 quarters
|
|
6814
CALL
Geron
GERN
$765M
| $64K | ﹤0.01% |
+28,400
| New | +$60.5K |
2017 Q1
0 quarters
|
|
6815
PUT
Mitsubishi UFJ Financial
MUFG
$258B
| $64K | ﹤0.01% |
+10,100
| New | +$66.1K |
2017 Q1
0 quarters
|
|
|
MRNS
6816
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $64K | ﹤0.01% |
+8,956
| New | +$48.1K |
2017 Q1
0 quarters
|
|
|
MTL
6817
PUT
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
| $64K | ﹤0.01% |
12,000
+1,300
| +12% | +$7.33K |
2016 Q4
1 quarter
|
|
|
ETRM
6818
DELISTED
EnteroMedics Inc.
ETRM
| $64K | ﹤0.01% |
+11,119
| New | +$82.2K |
2017 Q1
0 quarters
|
|
6819
CALL
Accuray
ARAY
$36.9M
| $63K | ﹤0.01% |
+13,200
| New | +$68.8K |
2017 Q1
0 quarters
|
|
6820
Calumet Specialty Products
CLMT
$4.87B
| $63K | ﹤0.01% |
16,469
-21,557
| -57% | -$85.3K |
2016 Q4
1 quarter
|
|
6821
Fate Therapeutics
FATE
$280M
| $63K | ﹤0.01% |
+13,746
| New | +$50.3K |
2017 Q1
0 quarters
|
|
6822
RadNet
RDNT
$5.49B
| $63K | ﹤0.01% |
+10,629
| New | +$63.2K |
2017 Q1
0 quarters
|
|
|
CSCI
6823
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
| $63K | ﹤0.01% |
+211
| New | +$62.1K |
2017 Q1
0 quarters
|
|
|
GAU
6824
PUT
Galiano Gold
GAU
$518M
| $62K | ﹤0.01% |
23,700
+7,200
| +44% | +$22.3K |
2016 Q4
1 quarter
|
|
|
NTBL
6825
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
| $62K | ﹤0.01% |
+323
| New | +$62K |
2017 Q1
0 quarters
|
|
Similar funds
Citadel Advisors's Q1 2017 Portfolio in Review
As of Q1 2017, Citadel Advisors held 8,634 positions worth $109B, up 11% from $99B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Citadel Advisors deployed $4.43B of net new capital in Q1 2017, opening 1,445 new positions and adding to 2,647 existing holdings. Its largest new stake was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, down from 63% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $482M trimmed.
- Citadel Advisors's largest Q1 2017 buy was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
- Citadel Advisors added most to Microsoft in Q1 2017, an estimated $529M increase.
- Citadel Advisors's biggest Q1 2017 reduction was Alphabet (Google) Class A, cutting an estimated $482M.
- Citadel Advisors fully exited Celgene Corp in Q1 2017, selling an estimated $341M.
- Citadel Advisors's ten largest holdings make up 19% of its $109B portfolio in Q1 2017.
- Citadel Advisors opened 1,445 new positions and closed 1,267 in Q1 2017.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $109B.
Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.